

Supplementary Figure 3. (**a**) Recombinant U1 snRNA expression *in vitro*. One µg shRNA/U1i construct was transfected in 24-wells plates containing approximately $2x10^5$ HEK293T cells. Two days after transfection, RNA was isolated and qPCR was performed with U1- and actin-specific primers. Exogenous U1 snRNA expression was calculated relative to mock-transfected cells. AH expressed shApoB with double H1/H4, AL expressed shApoB with double L4/L5, LH expressed shLuc1 with double H1/H4, and LL expressed shLuc1 with double L4/L5. Data are presented as mean of three technical replicates +SD. (**b**) MTT cell viability assay after transfection with increasing amounts (50-250 ng) of shRNA/U1i constructs. Transfections were carried out as described in Figure 4. MTT assay was performed two days after transfection. Percentage cell viability is depicted relative to the control pro-AAV cloning vector. None of the shRNA/U1i constructs affected cell viability. Cell-death-inducing puromycin (0-1.8 µg/mL) was added to separate wells as a positive control to create a killing curve. Data are presented as mean of six technical replicates ±SD. Similar transfections were carried out in the murine C2C12 muscle cell line, and resulted in equal luciferase inhibition and normal cell viability compared with HEK293T-transfected cells (data not shown).